Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017 Dec 7; 130(23):2475–2483.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019 Jan;94(1):133–143.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 Dec;93(12):1551–1560.
   PubMed Web of Science ®Google Scholar
• Szuber N, Mudireddy M, Nicolosi M, et al. 3023 mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019 Apr;94(4):599–610.
   PubMed Web of Science ®Google Scholar
• Masarova L, Bose P, Daver N, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017;59:110–116.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun;31(6):737–740.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Heaney ML, Najfeld V, et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012 Dec;36(12):1500–1504.
   PubMed Web of Science ®Google Scholar
• Bonifacio M, Stagno F, Scaffidi L, et al. Management of chronic myeloid leukemia in advanced phase. Front Oncol. 2019 Oct 25;9:1132.
   PubMed Web of Science ®Google Scholar
• Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017 Jul;92(7):1118–1128.
   PubMed Web of Science ®Google Scholar
• Dunbar A, Rampal R, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020 Jul 2; 136(1):61–70.
   PubMed Web of Science ®Google Scholar
• Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009 Nov 20;27(33):5587–5593.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26;125(9):1367–1376.
   PubMed Web of Science ®Google Scholar
• Pettit K, Odenike O. Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches. Expert Rev Hematol. 2016 Sep;9(9):851–859.
   PubMed Web of Science ®Google Scholar
• Khan M, Siddiqi R, Gangat N. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms. Leuk Res. 2017 Dec;63:78–84.
   PubMed Web of Science ®Google Scholar
• Odenike O. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018 Nov 29; 132(22):2339–2350.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Mudireddy M, Mannelli F, et al. Blast phase myeloproliferative neoplasm: mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 May;32(5):1200–1210.
   PubMed Web of Science ®Google Scholar
• Sengsayadeth S, Gatwood KS, Boumendil A, et al. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018;2(16):2127–2135.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vannucchi AM. Genetic risk assessment in myeloproliferative neoplasms. Mayo Clin Proc. 2017 Aug;92(8):1283–1290.
   PubMed Web of Science ®Google Scholar
• Schischlik F, Kralovics R. Mutations in myeloproliferative neoplasms their significance and clinical use. Expert Rev Hematol. 2017 Nov;10(11):961–973.
   PubMed Web of Science ®Google Scholar
• Lasho TL, Mudireddy M, Finke CM, et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018 Feb 27;2(4):370–380.
   PubMed Web of Science ®Google Scholar
• McNamara CJ, Panzarella T, Kennedy JA, et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Adv. 2018 Oct 23;2(20):2658–2671.
   PubMed Web of Science ®Google Scholar
• Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012 Aug;51(8):743–755.
   PubMed Web of Science ®Google Scholar
• Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012 May 10;119(19):4480–4485.
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010 Jan 28;362(4):369–370.
   PubMed Web of Science ®Google Scholar
• Marcellino BK, Hoffman R, Tripodi J, et al. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018 Dec 26;2(24):3581–3589.
   PubMed Web of Science ®Google Scholar
• McPherson S, McMullin MF, Mills K. Epigenetics in myeloproliferative neoplasms. J Cell Mol Med. 2017 Sep;21(9):1660–1667.
   PubMed Web of Science ®Google Scholar
• Ko TK, Javed A, Lee KL, et al. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood. 2020 Jun 25;135(26):2337–2353.
   PubMed Web of Science ®Google Scholar
• Thomas X, Elhamri M, Heiblig M. Emerging pharmacotherapies for elderly acute myeloid leukemia patients. Expert Rev Hematol. 2020;13(6):619–643.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Nice FL, Wedge DC, et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015 Nov;100(11):e438–42.
   PubMed Web of Science ®Google Scholar
• Bohl SR, Bullinger L, Rücker FG. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev Hematol. 2018 May;11(5):361–371.
   PubMed Web of Science ®Google Scholar
• Tognon R, Gasparotto EP, Neves RP, et al. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis. J Hematol Oncol. 2012 Feb 2;5:2.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gutzmer R, Kieran MW, et al. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019;76:41–50.
   PubMed Web of Science ®Google Scholar
• Solem CT, Bell TJ, Kwon Y, et al. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. Cancer. 2020 Jul 22. DOI:10.1002/cncr.33072
   PubMed Web of Science ®Google Scholar
• Holmström MO, Riley CH, Skov V, et al. Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. Oncoimmunology. 2018 Feb 27;7(6):e1433521.
   PubMed Web of Science ®Google Scholar
• Wang JC, Chen C, Kundra A, et al. Programmed cell death receptor (PD-1) ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res. 2019;79:52–59.
   PubMed Web of Science ®Google Scholar
• Fathi E, Sanaat Z, Farahzadi R. Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts. Blood Res. 2019;54(3):165–174.
   PubMed Web of Science ®Google Scholar
• Fathi E, Farahzadi R, Valipour B, et al. Cytokines secreted from bone marrow derived mesenchymal stem cells promote apoptosis and change cell cycle distribution of K562 cell line as clinical agent in cell transplantation. PLoS One. 2019;14(4):e0215678.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4(15):3528–3549.
   PubMed Web of Science ®Google Scholar
• Niscola P, Tendas A, Scaramucci L, et al. End of life care in hematology: still a challenging concern. Ann Palliat Med. 2014 Jan;3(1):7–11.
   PubMedGoogle Scholar
• Niscola P, Tendas A, Giovannini M, et al. Caring for terminal patients in haematology: the urgent need of a new research agenda. Support Care Cancer. 2015 Jan;23(1):5–7.
   PubMed Web of Science ®Google Scholar
• Niscola P, Tendas A, Efficace F. Early palliative care in patients with hematological malignancies: where do we go from here? J Pain Symptom Manage. 2018 Apr;55(4):e1–e2.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005 Feb 1;105(3):973–977.
   PubMed Web of Science ®Google Scholar
• Hilberink J, Hazenberg C, van den Berg E, et al. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: a single center experience of 355 consecutive patients. Leuk Res. 2019;80:33–39.
   PubMed Web of Science ®Google Scholar
• Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17;119(20):4614–4618.
   PubMed Web of Science ®Google Scholar
• Devillier R, Raffoux E, Rey J, et al. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2016 Feb;172(4):628–630.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684–2692.
   PubMed Web of Science ®Google Scholar
• Voso MT, Niscola P, Piciocchi A, et al. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. Eur J Haematol. 2016 Apr;96(4):344–351.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010 Nov 11;116(19):3735–3742.
   PubMed Web of Science ®Google Scholar
• Andriani A, Elli E, Trapè G, et al. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. Hematol Oncol. 2019 Aug;37(3):291–295.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos PT, Giannakopoulou N, Hatzidavid S, et al. Post-myelofibrosis acute myeloid leukemia effectively treated with a combination of ruxolitinib and 5-azacytidine. Oncol Res Treat. 2019;42(10):532–535.
   PubMed Web of Science ®Google Scholar
• Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep;39(9):950–956.
   PubMed Web of Science ®Google Scholar
• Niscola P, Abruzzese E, Trawinska MM, et al. Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation. Acta Oncol. 2017 Oct;56(10):1331–1333.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, Neri B, et al. Succesful decitabine treatment in unfit, elderly patients with acute myeloid leukemia following chronic myeloproliferative neoplasm. Acta Haematol. 2018;140(4):231–233.
   PubMed Web of Science ®Google Scholar
• Rampal RK, Mascarenhas JO, Kosiorek HE, et al. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Adv. 2018 Dec 26;2(24):3572–3580.
   PubMed Web of Science ®Google Scholar
• Alchalby H, Zabelina T, Stübig T, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the myeloproliferative neoplasm subcommittee of the CMWP of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2):279–281.
   PubMed Web of Science ®Google Scholar
• Marcellino B, Mascarenhas J. Management of advanced phase myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2019 Jul;17(7):405–411.
   PubMedGoogle Scholar
• Venton G, Courtier F, Charbonnier A, et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018 Mar;93(3):330–338.
   PubMed Web of Science ®Google Scholar
• Kröger N, Panagiota V, Badbaran A, et al. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017 Jul;23(7):1095–1101.
   PubMed Web of Science ®Google Scholar
• Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015 Nov;29(11):2126–2133.
   PubMed Web of Science ®Google Scholar
• Jain T, Mesa RA, Palmer JM. Allogeneic stem cell transplantation in myelofibrosis. Biol Blood Marrow Transplant. 2017 Sep;23(9):1429–1436.
   PubMed Web of Science ®Google Scholar
• Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood. 2008 Sep;112(5):1628–1637.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, de Lima M, Giralt S, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010;16(4):555–559.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010;34(9):1246–1249.
   PubMed Web of Science ®Google Scholar
• Cherington C, Slack JL, Leis J, et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012 Sep;36(9):1147–1151.
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood. 2013 Apr;121(14):2725–2733.
   PubMed Web of Science ®Google Scholar
• Cahu X, Chevallier P, Clavert A, et al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2014 Jun;49(6):756–760.
   PubMed Web of Science ®Google Scholar
• Takagi S, Masuoka K, Uchida N, et al. Allogeneic hematopoietic cell transplantation for leukemic transformation preceded by philadelphia chromosome-negative myeloproliferative neoplasms: a nationwide survey by the adult acute myeloid leukemia working group of the japan society for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016 Dec;22(12):2208–2213.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Partain DK, Palmer JM, et al. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol. 2018 May;93(5):649–654.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol. 2018 Apr;14(10):979–993.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke CM, et al. IDH1 and IDH2 mutation analysis in chronic-and blast-phase myeloproliferative neoplasms. Leukemia. 2010 Jun;24(6):1146–1151.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 Feb 14;133(7):676–687.
   PubMed Web of Science ®Google Scholar
• Huemer F, Melchardt T, Jansko B, et al. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. Eur J Haematol. 2019 May;102(5):437–441.
   PubMed Web of Science ®Google Scholar
• Niscola P, Noguera NI, Catalano G, et al. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy. Acta Oncol. 2019 Jun;58(6):888–890.
   PubMed Web of Science ®Google Scholar
• Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019 Oct 23;10:2040620719882822.
   Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019 Oct 22;3(20):2911–2919.
   PubMed Web of Science ®Google Scholar
• Wolska-Washer A, Robak T. Glasdegib in the treatment of acute myeloid leukemia. Future Oncol. 2019 Oct;15(28):3219–3232.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Tauchi T, Ritchie E, et al. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leuk Res. 2019;79:38–44.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, By K, Subramaniam S, et al. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019 Oct 15;25(20):6021–6025.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 Feb;33(2):379–389.
   PubMed Web of Science ®Google Scholar
• Cimen Bozkus C, Roudko V, Finnigan JP, et al. Immune checkpoint blockade enhances shared neoantigen-induced t cell immunity directed against mutated calreticulin in myeloproliferative neoplasms. Cancer Discov. 2019 Sep;9(9):1192–1207.
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, Phase II study. Cancer Discov. 2019 Mar;9(3):370–383.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Manshouri T, Mill CP, et al. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 Jun;33(6):1373–1386.
   PubMed Web of Science ®Google Scholar
• Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2019 Oct;111(2):192–199.
   PubMed Web of Science ®Google Scholar
• Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 May 12;4(9):1965–1973.
   PubMed Web of Science ®Google Scholar